In another study on prostate cancer, HOXA2, HOXA9, and HOXA10 were identified as critical genes, which were both abnormally expressed and associated with clinical outcomes of patients with prostate cancer (Song et al., 2022). This evidence concerns the gene HOXA9 and Familial prostate cancer.